2 undervalued mid-caps that could help you retire early

These two stocks have stunning potential, says G A Chester.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Specialist healthcare company BTG (LSE: BTG) issued a trading update ahead of its AGM today. The FTSE 250 firm said its strong performance in the year ended 31 March has continued into the new financial year.

It highlighted performance from its liver cancer treatment TheraSphere, and blood clot treatment device EKOS, and said that its antivenin CroFab has made a good start to the new snakebite season.

It advised that full-year guidance is unchanged. Chief executive Louise Makin commented: “We are on track to achieve double-digit product sales growth over the full financial year, driven by growth in our Interventional Medicine business.”

Near-term prospects

Given the in-line guidance, it’s no surprise BTG’s shares have barely moved on the day. Nevertheless, I believe the current price of 670p undervalues the business’s growth prospects, both in the near term and the longer term.

The forecast earnings consensus is 29.5p a share for the current year, 27.7% ahead of last year. This puts BTG on a price-to-earnings (P/E) ratio of 22.7 and a price-to-earnings growth (PEG) ratio of 0.8. The P/E is not excessive, while the PEG being below one indicates the stock is undervalued for the earnings it’s forecast to deliver. Near term, a 20% rise in the shares would take it closer to fair value

Long-term prospects

Looking beyond 2017/18, BTG appears well-placed to continue its strong growth. The company says it expects no let-up in double-digit product sales increases in the medium term.

This will be driven by a continuing strong performance from its interventional medicine business, aided by the anticipated opportunity from its varicose veins treatment Varithena, and its PneumRx Coil treatment for patients with severe emphysema, both of which are expected to reach important milestones this year.

In addition to fast-growing sales, the company expects to deliver an increasing gross margin, so profits should race higher at a great clip. With cash on the balance sheet (no debt) and fast-rising profits reinvested in the business (no dividend), I see BTG as a stock that could produce fantastic capital gains over the long term and I rate the shares a ‘buy’.

A different proposition

Aside from being in the FTSE 250, Caledonia Investments (LSE: CLDN) is a different proposition to BTG. For one thing, it’s an investment trust and for another, it targets both capital and income growth (it has delivered 50 consecutive years of dividend increases).

I believe this company’s shares are also undervalued (at 2,845p) and that its long-term prospects make this another stock that could help you retire early.

Hidden value

Caledonia holds many familiar stocks, such as Microsoft, Nestlé and British American Tobacco but it also has 30% of its portfolio in private companies, such as Gala Bingo and The Sloane Club, and a further 12% in private equity funds.

Caledonia’s last reported net asset value (NAV) per share was 3,403p at 30 June, so its shares are currently trading at a discount to NAV of 16.4%. This is attractive in its own right but the potential NAV is even higher, due to the private companies on the books. For example, Caledonia recently sold caravan park operator Park Holidays UK for net proceeds of £197m — a 47% premium to its carrying value of £134m.

Due to the discount to NAV and the potential additional ‘hidden value’ that could be realised over time, I rate Caledonia’s shares a ‘buy’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended BTG. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »